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Abstract: Of all the treatments currently used to lower intraocular pressure in glaucoma 
patients, filtration surgery is known to be the most effective. However, in a significant percentage 
of cases, the constructed channel closes due to excessive scar formation, resulting in surgical 
failure. The process of postoperative wound healing is characterized by the coagulative and 
inflammatory phase, followed by the proliferative and repair phase, and finally the remodeling 
phase. Perioperative antimitotic agents, such as mitomycin C and 5-fluorouracil, are known to 
modulate the process of wound healing and to improve surgical outcome, but they carry a risk 
of vision-threatening complications. New alternative strategies to prevent filtration failure, such 
as inhibition of transforming growth factor-β, vascular endothelial growth factor, and placental 
growth factor, have shown promising results in the improvement of surgical success. However, 
it remains necessary to broaden the therapeutic approach by focusing on combined therapies 
and on extended drug delivery.
Keywords: glaucoma filtration surgery, filtration failure, wound healing, wound modulating 
agents
Introduction
The most effective treatment to lower intraocular pressure (IOP) in glaucoma patients 
is glaucoma filtration surgery. Trabeculectomy, the reference procedure, is a surgical 
technique by which a tunnel is created between the anterior chamber and the subcon-
junctival space, with removal of a part of the trabecular meshwork. A controlled leaking 
area for aqueous humor is formed, called a filtration bleb. Although this procedure 
may be crucial in the management of glaucoma,1,2 it carries a risk of complications. 
Excessive postoperative wound healing of the conjunctiva and Tenon’s capsule, with 
subsequent scarring, is known to frequently lead to surgical failure,3 associated with 
poor postoperative IOP control and consequent progression of glaucomatous disc 
cupping and visual field loss.
Pharmacological enhancement of trabeculectomy using different antiscarring 
agents was found to significantly improve surgical success rates. Indeed, the use 
of 5- fluorouracil and mitomycin C, known as the gold standards in clinical practice, 
has improved the success rate significantly by enhancing bleb survival. However, 
long-term success rates for blebs supplemented with these antimitotics were not as 
promising as desired. Moreover, the nonspecific mechanism of action of these agents 
may result in severe vision-threatening side effects, such as corneal toxicity, thin-walled 
avascular blebs, blebitis, endophthalmitis, and hypotony. Therefore, there is still a need 
for alternative strategies to prevent filtration failure. In this review, an overview of the 
current wound healing modulation agents is provided, and new approaches to wound 
modulation that may improve glaucoma filtration surgery are discussed.
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Figure 1 Schematic overview of the process of wound healing and the most important molecules (growth factors, cytokines, and proteinases) involved.
Abbreviations: FGF, fibroblast growth factor; IL, interleukin; MMP, matrix metalloproteinase; PDGF, platelet-derived growth factor; PIGF, placental growth factor; TGF-β, 
transforming growth factor beta; VEGF, vascular endothelial growth factor; INFα2b, interferon alpha 2b.
Process of wound healing
Wound healing comprises a cascade of different processes that 
are closely linked, and includes a coagulative and inflamma-
tory phase, followed by a proliferation and repair phase, and 
finally a remodeling phase.4 Figure 1 gives a schematic over-
view of the wound healing process and the various  molecules 
(growth factors, cytokines, and proteinases) involved in the 
different phases. After injury, leakage of plasma proteins 
(fibrinogen, fibronectin, and plasminogen) and blood cells 
(red and white blood cells and platelets) from disrupted blood 
vessels takes place. Clotting factor activation leads to con-
version of fibrinogen to fibrin, to reduce blood loss. Clots as 
well as hormones (histamine, serotonin, prostaglandins and 
 leukotrienes), cytokines (eg,  interleukin-1 and interferon-
α2b) and growth factors (eg, vascular endothelial growth fac-
tor [VEGF], placental growth factor, platelet-derived growth 
factor, fibroblast growth factor, and transforming growth 
factor [TGF]-β), released during vascular injury, lead to cel-
lular migration and attraction of neutrophils, macrophages, 
and lymphocytes to the damaged tissue during the inflam-
matory phase. This results in a proliferative and repair phase 
during which endothelial cells and fibroblasts migrate into 
the site of injury. In this phase, angiogenesis and formation 
of granulation tissue occurs. Finally, remodeling of tissue 
takes place and involves the formation of scar tissue. Blood 
vessels regress over time, and fibroblasts induce crosslink-
ing of collagen type I and elastin, which leads to collagen 
supercoil formation and dense scar tissue.4,5 After trabeculec-
tomy, wound healing under the scleral flap may play a role 
in some cases, but Tenon fibroblasts are regarded as the key 
players in the initiation of wound healing and fibrotic scar 
formation.6 Although it is known that bleb failure in humans 
normally happens at around 2–3 months,7,8 proliferation of 
subconjunctival fibroblasts already occurs on postoperative 
days 3–5.9 The further development of conjunctival fibrosis, 
regulated by the release of a number of cytokines and growth 
factors, appears as a result of inflammation, angiogenesis, 
progressive fibroblast proliferation and migration, and 
 collagen deposition at the site of filtration.4
Modulators of wound healing  
in clinical practice
Gentle handling of tissue and control of intraoperative  bleeding 
lead to reduced fibroblast activity, but such preventive 
maneuvers are usually insufficient to prevent scarring in the 
long term.4 Therefore, various anti-inflammatory and 
 antiproliferative agents are used in clinical practice to inhibit 
wound healing and to improve bleb survival.
Anti-inflammatory agents
Inhibition of inflammation and wound healing by corti-
costeroids is largely mediated by suppression of leukocyte 
concentration and function, as well as by their effects on 
vascular permeability. This leads to less local tissue dis-
ruption, reduced mitogen and growth factor release, and 
less clot and fibrin production, resulting in diminished 
fibroblast activity and wound healing.4 Corticosteroids are 
therefore frequently used as anti-inflammatory agents after 
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in inhibition of DNA synthesis and  ultimately in cell 
death.18 Khaw et al showed that 5- fluorouracil is an effec-
tive inhibitor of fibroblast growth. A five-minute exposure 
resulted in arrest of growth and had a long-lasting effect on 
human Tenon fibroblasts.19 Animal studies demonstrated that 
adjunctive 5-fluorouracil following trabeculectomy resulted 
in prolonged bleb survival with decreased scarring and fibro-
blast proliferation compared with no 5-fluorouracil.20 Use of 
5-fluorouracil at high levels, however, frequently leads to cor-
neal toxicity and apoptosis, since 5-fluorouracil is toxic to all 
actively  replicating tissues, such as corneal epithelium.21
Mitomycin C
Mitomycin C (Kyowa Hakko Kirin Co., Ltd., Princeton, NJ, 
USA), is another chemotherapeutic agent with antiprolifera-
tive properties. It undergoes metabolic activation via reduc-
tion into an alkylating agent that cross-links DNA. Mitomycin 
C not only inhibits DNA replication, but also mitosis and syn-
thesis of proteins, since it can interfere with any phase in the 
cell cycle.4 Inhibition of the proliferative phase of the wound 
healing pathway by mitomycin C increases the success rate of 
glaucoma surgery, mainly through inhibition of proliferation 
of fibroblasts and endothelial cells.22 Importantly, different 
aspects of mitomycin C administration, including dose and 
exposure time, can determine the outcome of success and 
affect the wound healing process. It is indeed known that brief 
intraoperative application of mitomycin C (2–2.5 minutes) is 
as effective for improvement of surgical outcome as a long 
exposure (5 minutes),23,24 whereas a low dose of mitomycin C 
(0.002%) shows reduced effectiveness as compared with 
a higher dose (0.02%).25 In addition to dose and duration 
of application, the size of the surface area can also affect 
the surgical outcome. Indeed, a large area treated with 
mitomycin C is more effective in achieving and maintaining 
target IOP, and the incidence of bleb scarring is lower  compared 
with eyes with small areas of application.26–28  Moreover, 
Cordeiro et al reported that diffuse noncystic blebs were 
observed more often in rabbits treated with large sponges 
(8×10 mm) than in those treated with small sponges 
(4×2 mm).29 Khaw et al showed that mitomycin C is more 
potent than 5-fluorouracil.30,31 They found that fibroblasts 
cultured from rabbit samples treated with mitomycin C still 
induced inhibition of growth at one month, while fibroblasts 
from 5-fluorouracil-treated rabbits demonstrated full recov-
ery from growth arrest after 7 days. This can be explained 
by their different mode of action, since it is known that 
mitomycin C induces permanent apoptosis through activation 
of caspase-3 and caspase-9, Fas, Bad, and phosphorylated 
p53 in human Tenon fibroblasts, while this is not the case 
glaucoma filtration surgery. Theoretically, they carry a risk 
of inducing a steroid response, resulting in elevated IOP. 
It is known that approximately 18%–36% of the  general 
 population is  steroid-responsive, but this prevalence can 
increase to 46%–92% in patients with primary-open angle 
 glaucoma.10 It is clear that steroid-induced ocular  hypertension 
is associated with specific morphological changes in the trabe-
cular meshwork, such as an increased deposition of extracel-
lular matrix and altered trabecular meshwork cell function, 
which in turn will cause disturbed aqueous humor outflow and 
an increase in IOP.11 Although these morphological changes 
in the trabecular meshwork still exist after glaucoma filtra-
tion surgery, it is known that steroid response is less com-
mon after surgery, presumably because the aqueous humor 
bypasses the trabecular meshwork via the created channel. 
Indeed, it has been shown that aqueous flow after surgery 
is reduced through the trabecular pathway, and that after a 
successful trabeculectomy, the diameter of Schlemm’s canal 
decreases, most likely due to underperfusion of the trabecu-
lar meshwork.12,13 This may explain why only 17%–36% of 
operated glaucoma patients develop a steroid-induced rise in 
IOP after trabeculectomy,14 whereas the risk in nonoperated 
glaucoma patients is much higher (46%–92%).10 Moreover, 
a ten-year follow-up of a prospective randomized trial of 
postoperative corticosteroids after trabeculectomy showed 
that IOP was stabilized in 82.8% (38 of 46 eyes) of steroid-
treated eyes after successful glaucoma surgery.15 Finally, it 
has been suggested that the risk of a steroid response might 
increase after filtration failure, since the aqueous humor must 
again flow through the altered trabecular meshwork.16 Also, 
nonsteroidal anti-inflammatory drugs suppress the inflamma-
tory response in the process of wound healing, but are known 
to be less potent as compared with corticosteroids.17
Antimitotics
In the early 1980s, antimitotic agents, such as 5-fluorouracil 
and mitomycin C, were found to be effective in  inhibiting 
activation of fibroblasts. Although these agents have 
impacted the success rate of glaucoma filtration surgery, 
they carry a risk of vision-threatening complications. 
With lower levels of exposure, bleb-related complications 
are less frequent, but filtration failure is more common, 
 representing a trade-off between efficacy and safety.
5-Fluorouracil
The antiproliferative effect of 5-fluorouracil (Hoffman-La 
Roche Ltd., Basel, Switzerland), a chemotherapeutic agent, 
is mediated by antagonizing pyrimidine metabolism. It inter-
feres with the synthesis of thymidine nucleotides, resulting 
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after administration of 5-fluorouracil.32 Mitomycin C-related 
cytological toxicity and apoptosis has been associated with 
the development of thin-walled avascular blebs, which carry a 
risk of hypotony and endophthalmitis.33 Comparative clinical 
trials demonstrated that 5-fluorouracil was associated with 
fewer side effects than mitomycin C, but seemed to be less 
efficient in improving the surgical outcome.34–36
Altogether, although these anti-inflammatory and anti-
mitotic agents were found to be effective in inhibiting the 
process of wound healing in clinical practice, they are not 
sufficiently effective to satisfactorily inhibit scarring after 
filtering surgery, and some carry a risk of severe side effects. 
Therefore, there is still a need for new approaches in modula-
tion of wound healing to prevent filtration failure.
State of the art in modulation  
of wound healing
The aqueous humor flowing through the constructed channel 
into the bleb after glaucoma surgery contains a large number 
of growth factors. It is known that the presence of growth 
factors in the aqueous humor of patients with glaucoma can 
increase the proliferation of Tenon fibroblasts by 60% com-
pared with the aqueous humor of normal persons.37 As such, 
pre-existing elevated aqueous levels of these growth factors 
may put patients with glaucoma at a higher risk of scarring 
after filtration surgery. Therefore, the upregulated growth 
factors in the aqueous humor of patients with glaucoma can 
be considered as potential targets in the development of new 
wound modulation agents. Indeed, a number of growth fac-
tor inhibitors have been investigated to improve the surgical 
outcome after glaucoma filtration surgery. Table 1 represents 
an overview of the new wound modulation agents.
inhibition of TGF-β
TGF-β is a key cytokine in the process of wound healing 
and has been found to be present at significantly higher 
levels in the aqueous humor of patients with glaucoma 
than in that of normal individuals.38 Moreover, TGF-β2 is 
known to stimulate proliferation of human Tenon  fibroblasts 
in vitro and to enhance fibroblast-mediated collagen 
 contraction.39  Therefore, the strategy of inhibiting this 
growth factor has been extensively investigated by a group 
led by Professor PT Khaw (Moorfields Eye Hospital and 
UCL Institute of  Ophthalmology, London, UK). Blocking 
TGF-β2 with a recombinant human monoclonal antibody 
(CAT-152,  Cambridge Antibody Technology, Cambridge, 
UK) seemed promising with regard to proliferation of Tenon 
fibroblasts and in an animal model. Khaw’s group investi-
gated CAT-152 as an adjunct to glaucoma filtration surgery 
in a rabbit model and showed that repeated subconjunctival 
injections (1 mg/mL on  postoperative days 0, 1, 2, 3, and 7) 
significantly improved the surgical outcome and bleb survival 
compared with controls. Histologically, CAT-152-treated 
eyes showed less collagen deposition and clear evidence 
of bleb formation, without side effects.40 A clinical study 
was initiated but was terminated prematurely due to lack of 
efficacy at the dose used (1 mg/mL).41 Decorin, a naturally 
occurring TGF-β inhibitor, also significantly altered conjunc-
tival scarring and the surgical outcome of glaucoma filtra-
tion surgery in rabbits, but no clinical data are available as 
yet.42 Inhibition of TGF-β2 by other agents, such as suramin 
(Bayer AG, Leverkusen, Germany),43,44 tranilast (Kissei Phar-
maceutical Co., Ltd., Matsumoto City, Japan),45–47 lovastatin 
(Merck & Co., Inc., Whitehouse Station, NJ, USA),48 and 
ALK5 inhibitors,49,50 has also been attempted in in vitro and 
animal studies, with promising results. A novel approach 
for targeting the TGF-β signaling pathway, currently under 
investigation, is the use of microRNA;51 however, confirma-
tion in animal studies is required.
inhibition of veGF
VEGF is known to play an important role in scar formation.52 
Increased concentrations of VEGF have been demonstrated 
in the aqueous humor from eyes of patients with glaucoma 
when compared with nonglaucomatous controls.53–55 
In addition to being a potent inducer of angiogenesis, 
VEGF promotes the migration of inflammatory cells 
(such as neutrophils and macrophages) and fibroblasts. 
This growth factor indirectly stimulates fibrosis via 
angiogenesis, and also has a direct effect on the activ-
ity of fibroblasts.56–58 Therefore, VEGF inhibitors were 
investigated by several groups as a potential antiscarring 
adjunct to filtration surgery.
Our group showed for the first time in a rabbit model 
of glaucoma filtration surgery that a single subconjunctival 
(2.5 mg) and intracameral (5 mg) injection of bevacizumab 
(Genentech, Inc., San Francisco, CA, USA) was effective 
in improving the outcome of glaucoma  surgery by increasing 
bleb area and survival. This was associated with a reduction 
in angiogenesis during the initial phase of healing and with 
diminished fibrosis in the later stages.53 When compared with 
blebs treated with 5-fluorouracil (5 mg), those treated with the 
VEGF inhibitor (1.25 mg) survived longer,59 and combining 
bevacizumab (2.5 mg) and 5-fluorouracil (5 mg) resulted 
in 100% bleb survival and a greater antifibrotic effect com-
pared with monotherapy using each inhibitor.60 Importantly, 
the various VEGF inhibitors available differ in their isoform 
selectivity, with implications for both efficacy and safety. 
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Table 1 New wound modulation agents
Inhibitor Mechanism of action Phase of wound healing Study Reference
CAT-152 Antibody against TGF-β2 Inflammation, fibrosis in vitro (HTF), rabbit, phase iii trial 40,41
Decorin inhibition of TGF-β2 Inflammation, fibrosis Rabbit 42
Suramin inhibition of TGF-β, PDGF, and FGF Inflammation, fibrosis Rabbit, case series 43,44
Tranilast inhibition of TGF-β, iL-1, and PGe2 Inflammation, fibrosis in vitro (RTF), rabbit, pilot study 45–47
Lovastatin inhibition of Rho pathway of TGF-β Inflammation, fibrosis in vitro (HTF) 48
ALK inhibitor inhibition of ALK signaling of TGF-β Inflammation, fibrosis in vitro (RTF), rabbit 49,50
microRNA Gene suppression of TGF-β Fibrosis in vitro (HTF) 51
Pegaptanib Aptamer against veGF165 Angiogenesis in vitro (HTF and RTF), rabbit 61
Ranibizumab Fab fragment against all veGF isoforms Angiogenesis, fibrosis Pilot study 99
Bevacizumab Antibody against all veGF isoforms Angiogenesis, fibrosis in vitro (HTF and RTF), rabbit,  
case reports and series,  
pilot study, RCT
53,59,60, 
62–75,97, 
98,100
5D11D4 Antibody against PlGF Inflammation, angiogenesis, 
fibrosis
in vitro (MTF), mouse 76
Y-27932 inhibition of ROCK Inflammation, fibrosis in vitro (HTF), rabbit 93,94
PDT Phototoxicity of Tenon fibroblasts Angiogenesis, fibrosis in vitro (HTF), rabbit,  
pilot study, RCT
101–104
Saratin inhibition of platelet adhesion Coagulation, fibrosis Rabbit 105,106
Sonepcizumab Antibody against SiP Fibrosis Rabbit 107
Doxycycline inhibition of MMP-1, MMP-2, MMP-8,  
MMP-9, MMP-13
Inflammation, fibrosis Rabbit 108
Pirfenidone inhibition of TGF-β, CTGF, PDGF, TNF-α Inflammation, fibrosis in vitro (HTF), rabbit 109,110
Tacrolimus immunosuppressive agent Inflammation, fibrosis Rabbit 111
Octreotide Octapeptide of somatostatin Inflammation, fibrosis Rabbit 111
Abbreviations: HTF, human Tenon fibroblasts; RTF, rabbit Tenon fibroblasts; RCT, randomized controlled trial; MTF, murine Tenon fibroblasts; PDT, photodynamic 
therapy; PlGF, placental growth factor; MMP, matrix metalloproteinase; VEGF, vascular endothelial growth factor; IL, interleukin; PGE2, prostaglandin E2; FGF, fibroblast 
growth factor; TNF-α, tumor necrosis factor alpha; TGF-β, transforming growth factor beta; PDGF, platelet-derived growth factor; CTGF, connective tissue growth factor; 
ALK, anaplastic lymphoma kinase; CAT-152, lerdelimumab; ROCK, Rho-associated protein kinase.
Based on their VEGF isoform targets, two types of VEGF 
inhibitors have been identified, ie, selective and nonselective. 
The effect of pegaptanib (Pfizer Inc., New York, NY, USA), 
a selective VEGF
165
 inhibitor, on surgical outcome in a rabbit 
model of glaucoma surgery was less pronounced than that 
of nonselective VEGF inhibition, due to a retained action of 
the VEGF
121
 and VEGF
189 
isoforms. It is indeed known that 
Tenon fibroblasts proliferation is mainly induced by these 
isoforms, while VEGF
165
 has less pronounced effects on 
Tenon fibroblasts.61
Meanwhile, a number of clinical case reports and case 
series have also shown a beneficial effect of subconjunctival 
(1, 1.25, and 2.5 mg) and topical (5 mg/mL) bevacizumab, 
a nonselective VEGF inhibitor, in reducing IOP and improv-
ing the surgical outcome.62–67 These studies also demonstrated 
that the antibody against VEGF is safe for ocular use. An early 
pilot study to evaluate a single subconjunctival bevacizumab 
injection (1.25 mg) demonstrated that this VEGF inhibitor is 
a potential adjunctive treatment for reducing the incidence 
of bleb failure after trabeculectomy. Six-month outcomes 
showed that trabeculectomy was successful in terms of IOP 
control in eleven of 12 eyes (92%), with an average IOP 
reduction of 52%.68 This beneficial effect was confirmed 
in more recent studies indicating no significant differences 
between subconjunctival bevacizumab (1.25 and 2.5 mg) and 
mitomycin C (0.03% for 3 minutes) in terms of  morphological 
bleb features and IOP-lowering.69,70
On the other hand, four further pilot studies showed that 
administration of bevacizumab (0.2 and 1.25 mg) during 
trabeculectomy did not affect IOP differently from  placebo71 
or 5-fluorouracil (5 and 7.5 mg).72–74 Notably, all these studies 
included small numbers of patients or had a short follow-up 
duration, meaning that they lacked the necessary power to 
draw firm conclusions. Therefore, our group at the University 
Hospitals of Leuven performed a prospective, randomized, 
double-blind, placebo-controlled trial in which a 12-month 
follow-up was undertaken in 138 patients, 69 of whom were 
treated with bevacizumab (1.25 mg by intracameral injec-
tion). The absolute success rate was higher in the bevaci-
zumab group than in the placebo group (71% versus 51%, 
respectively), with the need for IOP-lowering interven-
tions (needlings) being lower after bevacizumab treatment 
(12% versus 33%).75 Figure 2 shows blebs from the beva-
cizumab and placebo groups at 6 months of follow-up. 
Bevacizumab-treated eyes showed less vascularity than those 
treated with placebo. These recent insights open up  promising 
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Figure 2 Representative blebs from (A) bevacizumab group and (B) placebo group showing less vascularity in the bevacizumab-treated eye at 6 months postoperatively. 
Note: Reproduced from intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study. vandewalle e, Abegao Pinto L, van Bergen T, 
et al, vol 98, pages 73–78, Copyright © 2014 with permission from BMJ Publishing Group Ltd.75
perspectives for the use of anti-VEGF therapy to prevent 
filtration failure after glaucoma surgery.
inhibition of placental growth factor
Importantly, although bevacizumab could improve the 
surgical outcome by inhibiting angiogenesis and deposition 
of collagen, and VEGF is known to have proinflamma-
tory properties, neither selective nor nonselective VEGF 
inhibition could reduce inflammation, another important 
process in postoperative healing.53,61 Our group showed that 
the upregulated levels of aqueous placental growth factor 
after administration of bevacizumab might explain why 
anti-VEGF therapy was not sufficient to reduce the inflam-
matory response after glaucoma surgery. Indeed, aqueous 
placental growth factor levels were significantly upregulated 
in patients with glaucoma compared with control subjects. 
Moreover, intracameral injection of anti-placental growth 
factor antibody (5.2 µg, ThromboGenics NV, Leuven, 
Belgium) effectively improved the surgical outcome in a 
mouse model of trabeculectomy, by increasing the bleb 
area and survival after surgery compared with an irrelevant 
antibody control and with the VEGF-R2 antibody. The effect 
on surgical outcome was associated with a decreased angio-
genesis, fibrosis, and importantly, inflammation. Therefore, 
inhibition of placental growth factor might theoretically be 
even more effective than inhibition of VEGF, due to the 
additional effect on inflammation.76
Other growth factors, cytokines,  
and proteinases
Several other molecules, including growth factors (eg, platelet- 
derived growth factor) cytokines (eg, interleukin-6, 
interleukin-8, and tumor necrosis factor-α), and matrix 
 metalloproteinases (eg, MMP-2 and MMP-3) have been 
reported to be upregulated after glaucoma filtration 
surgery.77–80 Different studies have shown that these fac-
tors can stimulate proliferation of Tenon fibroblasts in 
vitro.81,82 Moreover, inhibition of some of these factors reduced 
growth of Tenon fibroblasts83 and improved surgical outcome 
in a rabbit model of glaucoma.84,85 However, none of these 
inhibitors have reached clinical trials. This can probably be 
explained by the fact that upregulation of TGF-β2 and VEGF 
in patients with glaucoma  correlates strongly with surgical 
failure, whereas other factors (eg, MMP-1, interleukin-6, and 
interleukin-8) are associated with surgical success.86
inhibition of ROCK
Rho kinases (ROCK 1 and 2) are major downstream 
 effectors of Rho-GTPase proteins and mediate a number 
of important cellular functions associated with cytoskel-
etal rearrangement, such as cell morphology, motility, 
adhesion, contraction, and cytokinesis.87 It is known that 
ROCK plays an important role in a number of wound heal-
ing processes, ie, inflammation, angiogenesis, and fibrosis. 
Administration of ROCK inhibitors on lipopolysaccharide-
stimulated inflammatory cells decreased the activation 
of NF-κβ and subsequently blocked the generation of 
proinflammatory cytokines, such as interleukin-1β/6 and 
tumor necrosis factor-α.88–90 Increased expression of RhoA 
in endothelial cells also significantly enhanced migra-
tion and angiogenic capacity in vitro, which suggests 
an important role for the Rho/ROCK pathway in these 
 processes.91 Furthermore, van Niew-Amerongen et al showed 
demonstrated that inhibition of the Rho/ROCK pathway 
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attenuated VEGF-mediated migration and angiogenesis 
in vitro.92 Importantly, in vitro studies also showed that 
contractility of Tenon fibroblasts is essential in the transdif-
ferentation into myofibroblasts. Inhibition of the Rho/ROCK 
pathway by specific kinase inhibitors (Y-27632 [Novartis 
AG, Basel, Switzerland], HA-1077 [Santen Pharmaceutical 
Co., Ltd., Osaka, Japan], H-1152 [Calbiochem®; Merck 
KGaA, Darmstadt, Germany], and ML-7 [Merck KGaA]) 
is known to counteract this contraction by blocking TGF-β 
or lysophospholipid acid-induced activation of Tenon 
fibroblasts.93,94 Secondly, Honjo et al showed that topical 
treatment with the ROCK inhibitor Y-27632 had profound 
effects on surgical outcome in a rabbit model of glaucoma 
surgery. Histological examination revealed that blebs 
treated with Y-27632 lacked significant collagen deposition 
compared with vehicle treatment.93 As such, ROCK inhibi-
tors could strengthen our armamentarium to improve the 
effectiveness of filtration surgery, because these  inhibitors 
have the potency to interfere at different levels of the wound 
healing process.
Future perspectives
Although bevacizumab has been proven to be effective in 
reducing wound healing after filtering glaucoma surgery 
in a prospective clinical trial, mitomycin C is still the most 
common antifibrotic agent used during trabeculectomy in 
routine clinical practice. This study may represent a break-
through in the quest for novel antifibrotic strategies in filter-
ing surgery; however, some additional questions remain to 
be answered. The most optimal route of administration of 
anti-VEGF drugs is still unknown. Nomoto et al showed 
that, despite lower maximal concentrations of bevacizumab 
after subconjunctival injection in the rabbit eye, the intraocu-
lar half-life was higher after subconjunctival injection as 
compared with intravitreal injection.95 Ambati et al showed 
that immunoglobulin G antibodies have a relatively high 
scleral permeability.96 Since bevacizumab is an immuno-
globulin G1 antibody, it should penetrate intraocular tissues via 
the sclera, which might then work as a sustained-release 
mechanism. Recent studies in a rabbit model of glaucoma 
surgery showed that postoperative subconjunctival injec-
tion of bevacizumab was more effective than intravitreal 
administration.97 It also remains unknown whether bevaci-
zumab could replace antimitotics in clinical practice, or if it 
should be considered as an adjunctive to antimitotics. Although 
some small comparative69,70,98 and complementary studies99,100 
have been performed, large randomized clinical trials are 
still lacking.
A variety of alternative antiscarring strategies (Table 1), 
such as photodynamic therapy,101–104  saratin (Merck 
KGaA),105,106 sonepcizumab (Lpath, Inc., San Diego, CA, 
USA),107 doxycycline (Pfizer Inc.),108 pirfenidone (InterMune, 
Brisbane, CA, USA),109,110  tacrolimus ( Astellas Pharma 
Inc., Tokyo, Japan),111 and  oct reotide (Novartis),111 have 
also shown promising results by improving the outcome of 
surgery in a standard rabbit model. Although many agents 
have been evaluated in preclinical models for glaucoma 
filtration surgery, few have been found to be beneficial in 
large prospective comparative clinical trials and none have 
replaced mitomycin C or 5-fluorouracil in clinical practice 
so far. Therefore, it is necessary to broaden the therapeutic 
approach, given that treatment with a single agent may lead 
to drug resistance. Indeed, because of the complexity of the 
wound healing process,4,5 it is possible that targeting one 
molecule may be insufficient to impede the wound healing 
process due to the upregulation of other growth factors. It has 
been suggested that  mitomycin C can upregulate proinflam-
matory,  proangiogenic, and/or  profibrotic factors. There-
fore,  combining mitomycin C with drugs that block these 
upregulated profibrotic growth factors may offer promising 
complementary efficacy and allow a lower dose of mitomycin 
C to be used, with fewer side effects.
Finally, wound healing is a relatively slow process 
involving interaction between the antiscarring agent and the 
target tissue (Tenon’s capsule) for several weeks to months. 
Therefore, future research should focus on the develop-
ment of targeted drug delivery systems that improve and/or 
prolong contact between the target tissues and the antiscar-
ring molecules. A few studies have already been published 
in which a slow-release formulation of 5-fluorouracil is 
described. Collagen plugs,112 polyesters,113 and amniotic 
membranes114 containing the antimitotic agent were shown 
to induce a prolonged effect on bleb survival in the standard 
rabbit model. The effect of a sustained-release dexametha-
sone implant (Ozurdex®, Allergan, Irvine, CA, USA) on 
postoperative wound healing was also investigated in this 
animal model, and was found to be effective in prolonging 
bleb survival. However, mitomycin C-treated blebs showed 
significantly longer survival compared with Ozurdex-treated 
blebs.115
Khalili et al developed a new solid tissue tablet that 
provides prolonged release of bevacizumab in vitro, and an 
in vivo study showed substantially prolonged bleb survival 
compared with mitomycin C in the rabbit model.116 Thus, this 
antibody tablet has the potential to prolong local antibody 
release and exert a significant biological effect. These data are 
Clinical Ophthalmology 2014:8submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
864
van Bergen et al
very promising, but further studies are required. If success-
ful, such improved drug delivery systems might significantly 
improve the efficacy of known antiscarring molecules and 
possibly decrease their side effects.
Conclusion
Failing filtering surgery due to an excessive healing reaction 
is still a considerable problem in ophthalmology, and con-
tributes to progressive vision loss in patients with glaucoma. 
Although a number of studies have demonstrated that many 
antifibrotic agents can reduce postoperative wound healing in 
the preclinical setting, bevacizumab is the only agent that has 
been proven to be effective in a prospective randomized clini-
cal trial. Further research should focus on targeting multiple 
steps of the wound healing process by use of combination 
therapy and also on new methods of extended drug delivery 
to improve the efficacy of the known antiscarring agents. 
Finally, we should be cautious when extrapolating preclini-
cal findings to the management of human disease. Animal 
models are not precise replicas of human pathology, and the 
pharmacokinetics and half-lives of the therapeutic agents 
might differ between animals and human eyes. Therefore, 
further clinical trials in humans with long-term follow-up and 
inclusion of comparative controls are required.
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